Results Released for Dry Eye Trial with Lifitegrast

Shire announced results from its Phase 3 OPUS-2 study and Phase 3 SONATA safety study investigating lifitegrast (5.0% ophthalmic solution) in adults with dry eye disease.

Abrams Royal Pharmacy Recalls All Sterile Products

Abrams Royal Pharmacy is voluntarily recalling all unexpired lots of sterile products due to concerns of lack of sterility assurance.

Lifitegrast Effective for Dry Eyes in Trials

Shire announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution for dry eyes.

OTC Eye Drops Recalled Due to Possible Contamination

Altaire is voluntarily recalling nine lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution, an OTC product used to relieve dry eyes.

High Pain Sensitivity Linked to Dry Eye Disease Symptoms

Pain sensitivity and pain tolerance are associated with symptoms of dry eye disease (DED).

Ocular Complications Common After Pediatric HSCT

For pediatric patients undergoing hematopoietic stem cell transplantation (HSCT), complications are common, but are generally mild and self-limiting.

Overused Ophthalmology Tests, Treatments Identified

The American Academy of Ophthalmology (AAO) is participating in the Choosing Wisely campaign and has identified five tests and treatments that may be overused.

Phase 3 Study Update of Lifitegrast for Dry Eye

SARcode Bioscience announced topline results from OPUS-1, a pivotal Phase 3 study of lifitegrast ophthalmic solution, 5%, vs. placebo for the treatment of dry eye disease.

Puralube ophthalmic ointment available OTC for dry eye

Fera announced that Puralube (white petrolatum and mineral oil), a preservative free ophthalmic ointment, is available again to relieve the symptoms of dry eye.

Phase 2 study of RGN-259 for the treatment of dry eye

RegeneRx Biopharmaceuticals announced that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease.

Systane Balance lubricant eye drops for Meibomian Gland Dysfunction

Alcon announced that it has expanded its Systane product line with the launch of Systane Balance lubricant eye drops for evaporative dry eye in patients with Meibomian Gland Dysfunction (MGD).

Phase 2 study of Remura for the treatment of dry eye disease

ISTA Pharmaceuticals announced the results from its Phase 2 trial of Remura (bromfenac ophthalmic solution) for the treatment of dry eye disease.

Sign Up for Free e-newsletters